mdl 100240 has been researched along with icatibant in 2 studies
| Studies (mdl 100240) | Trials (mdl 100240) | Recent Studies (post-2010) (mdl 100240) | Studies (icatibant) | Trials (icatibant) | Recent Studies (post-2010) (icatibant) |
|---|---|---|---|---|---|
| 21 | 9 | 0 | 1,137 | 49 | 259 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bennett, T; Brunner-Ferber, F; Gardiner, SM; Kemp, PA | 1 |
| Agabiti-Rosei, E; Bianchi, R; De Ciuceis, C; Nussdorfer, GG; Paiardi, S; Porteri, E; Rezzani, R; Rizzoni, D; Rodella, L; Rossi, GP; Sleiman, I; Sticchi, D | 1 |
2 other study(ies) available for mdl 100240 and icatibant
| Article | Year |
|---|---|
Comparative effects of the dual metallopeptidase inhibitor, MDL 100,240 and of enalaprilat on regional and on cardiac haemodynamics in conscious, hypertensive, transgenic ((mRen-2)27) rats.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Benzazepines; Bradykinin; Enalaprilat; Hemodynamics; Hypertension; Male; Metalloendopeptidases; Protease Inhibitors; Pyridines; Rats | 1997 |
Bradykinin and matrix metalloproteinases are involved the structural alterations of rat small resistance arteries with inhibition of ACE and NEP.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Benzazepines; Bradykinin; Bradykinin Receptor Antagonists; Disease Models, Animal; Drug Interactions; Hypertension; Immunohistochemistry; Male; Matrix Metalloproteinases; Mesenteric Arteries; Myography; Neprilysin; Pyridines; Ramipril; Rats; Rats, Sprague-Dawley; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Vascular Resistance; Vasoconstriction | 2004 |